FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1273-1274 October 26, 2000 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Mullon, J. PubMed Citation

To the Editor: Parasitic infections remain scourges to people worldwide.¹ Increasing international travel and immigration from countries where parasitic infections are endemic ensure that clinicians in the United States will be required to treat patients with these infections. Although safe and inexpensive treatments are available for most of these infections,² there are few incentives for the pharmaceutical industry to make these drugs available in the United States.

In the past 10 years, several drugs — quinacrine, the most effective medication for giardia infection; niclosamide, the main treatment for tapeworm infection; and diethylcarbamazine, the best treatment for lymphatic filariasis — have . . . [Full Text of this Article]

References

This article has been cited by other articles:

• WHITE, A. C. JR. (2003). NITAZOXANIDE: AN IMPORTANT ADVANCE IN ANTI-PARASITIC THERAPY. Am J Trop Med Hyg 68: 382-383 [Full Text]  
• Berlin, C. (2001). Are We Losing Good Drugs?. CLIN PEDIATR 40: 325-326